One CRISPR dose nearly eliminated swelling attacks in hereditary angioedema
Published · Researched 2026-09-22
What happened (dated facts)
In a Phase 2 trial of 27 adults with hereditary angioedema (HAE) — a genetic disease causing unpredictable, potentially life-threatening swelling attacks — a single 50 mg dose of the in-vivo CRISPR therapy NTLA-2002 reduced monthly attack rates by 77–81%, and 8 of 11 patients in the key cohort were completely attack-free during the main observation window. No treatment-attributed serious adverse events were reported. The therapy works by editing the KLKB1 gene in the liver to durably lower kallikrein, the driver of attacks. Phase 3 testing is still required and the therapy is investigational.
Why it is genuinely positive
HAE attacks can close airways without warning; patients live around the constant threat of the next one. A one-time infusion that left most treated patients attack-free — with no serious safety signals — points toward a functional cure for a disease that currently demands lifelong management.
Social pulse
On Threads (searched 2026-09-22), the HAE CRISPR therapy was circulating in biotech conversation: @42investing posted "$NTLA just hit a major milestone with FDA Priority Review for nexigebart, its CRISPR-based therapy for hereditary angioedema," and @longevity.technology shared "A one-time CRISPR treatment dramatically reduced attacks in hereditary angioedema, marking a major milestone for genetic medicine." (Nexigebart is NTLA-2002's commercial name.) The story is genuinely circulating via investor and longevity-tech accounts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Medical Update Online report on the Phase 2 results (https://medicalupdateonline.com/2024/10/gene-editing-therapy-shows-promise-for-hereditary-angioedema/), October 2024. Proves: 27 adults; 77–81% attack reduction; 8/11 attack-free in main window; no treatment-attributed SAEs.
- Social sources: Threads — @42investing (FDA Priority Review milestone for nexigebart/NTLA-2002); @longevity.technology (one-time CRISPR treatment reducing HAE attacks). Proves: the therapy is circulating via investor and biotech accounts.
- Positivity check: measured near-elimination of attacks with a clean safety readout — genuine, with Phase 3 still required stated clearly.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| Trial | Phase 2, 27 adults with hereditary angioedema | Medical Update Online | 2024-10 |
| Dose | Single 50 mg infusion (NTLA-2002, KLKB1 editing) | Medical Update Online | 2024-10 |
| Attack reduction | 77–81% fewer monthly attacks | Medical Update Online | 2024-10 |
| Attack-free | 8 of 11 patients attack-free in main observation window | Medical Update Online | 2024-10 |
| Safety | No treatment-attributed serious adverse events | Medical Update Online | 2024-10 |
UNVERIFIED points
- Social-layer posts about NTLA-2002 were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: Medical Update Online report on the Phase 2 results ( — retrieval date not recorded